Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Vomiting 2Uterine Cervical Neoplasms 2Nausea 2Condylomata Acuminata 2Breast Neoplasms 2Sezary Syndrome 1Renal Insufficiency 1Osteoarthritis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Kidney Failure, Chronic 1Cancer Pain 1Bone Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

pembrolizumab 44Carboplatin 28Cisplatin 26Paclitaxel 24Bevacizumab 21human papillomavirus vaccine, L1 type 16, 18 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14atezolizumab 11Papillomavirus Vaccines 11Nivolumab 10tisotumab vedotin 8Vaccines, Synthetic 8Gemcitabine 8Colposcopy 8Topotecan 7fludarabine 6Vaccines 6Injections 6Cyclophosphamide 6spartalizumab 5balstilimab 5Pemetrexed 5Irinotecan 5Fulvestrant 5Docetaxel 5zimberelimab 4durvalumab 4Vinorelbine 4Ipilimumab 4Interleukin-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Neoplasms × Duration of Therapy × Clear all
NCT00092482 2017-03-22

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
3,882 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00517309 2017-03-22

FUTURE

Merck Sharp & Dohme LLC

Phase 3 Completed
1,877 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡